key: cord-1044178-jlwmuyz8
authors: Chen, Ting; Fei, Cheng-Yin; Chen, Yi-Ping; Sargsyan, Karen; Chang, Chun-Ping; Yuan, Hanna S.; Lim, Carmay
title: Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram/Ebselen and Remdesivir
date: 2021-03-26
journal: ACS Pharmacol Transl Sci
DOI: 10.1021/acsptsci.1c00022
sha: 30591da9a357ee1ac29d5e4f598aa9d490c4747f
doc_id: 1044178
cord_uid: jlwmuyz8

[Image: see text] The SARS-CoV-2 replication and transcription complex (RTC) comprising nonstructural protein (nsp) 2–16 plays crucial roles in viral replication, reducing the efficacy of broad-spectrum nucleoside analog drugs such as remdesivir and evading innate immune responses. Most studies target a specific viral component of the RTC such as the main protease or the RNA-dependent RNA polymerase. In contrast, our strategy is to target multiple conserved domains of the RTC to prevent SARS-CoV-2 genome replication and to create a high barrier to viral resistance and/or evasion of antiviral drugs. We show that the clinically safe Zn-ejector drugs disulfiram and ebselen can target conserved Zn(2+) sites in SARS-CoV-2 nsp13 and nsp14 and inhibit nsp13 ATPase and nsp14 exoribonuclease activities. As the SARS-CoV-2 nsp14 domain targeted by disulfiram/ebselen is involved in RNA fidelity control, our strategy allows coupling of the Zn-ejector drug with a broad-spectrum nucleoside analog that would otherwise be excised by the nsp14 proofreading domain. As proof-of-concept, we show that disulfiram/ebselen, when combined with remdesivir, can synergistically inhibit SARS-CoV-2 replication in Vero E6 cells. We present a mechanism of action and the advantages of our multitargeting strategy, which can be applied to any type of coronavirus with conserved Zn(2+) sites.

T he COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is affecting billions of people around the world. The recent approval of several vaccines against SARS-CoV-2 1 would help to reduce transmission. However, it is not known how long immunity stays and whether the vaccinated person, though protected from COVID-19, may still carry the SARS-CoV-2 for some period and possibly infect others. To treat hospitalized COVID-19 patients, antivirals such as small-molecule drugs and neutralizing antibodies targeting SARS-CoV-2 are needed. Neutralizing antibodies derived from convalescent plasma obtained from a COVID-19 patient have shown only moderate success in clinical studies. 2 De novo antiviral development is lengthy and costly. A shortcut approach is to repurpose widely available, inexpensive drugs that can be easily administered against SARS-CoV-2. Most studies target a single SARS-CoV-2 protein 3 such as the spike protein that mediates cell entry, 4 the main protease (M pro ) 5, 6 or the papain-like protease (PL pro ) 7 that cleaves the viral polyprotein into its constituent proteins, or the RNA-dependent RNA polymerase (RdRp) that catalyzes viral RNA synthesis. 8, 9 However, the virus may evade antiviral drugs that target a single viral protein by mutations 10 or deletions, 11 and the spike receptor-binding domain is the most variable. 12 One strategy is to create a high barrier to viral resistance/evasion of antiviral drugs by targeting sites with slow mutation rates in the multiprotein SARS-CoV-2 replication and transcription complex (RTC) that enables viral replication and transcription (see below). Here, we show that FDA-approved drugs (disulfiram/ebselen and remdesivir) can synergistically inhibit SARS-CoV-2 replication by targeting conserved sites in multiple nonstructural proteins (nsps) constituting the core of the RTC.

SARS-CoV-2 is an enveloped β-coronavirus containing a positive-sense single-stranded RNA (+ssRNA) genome that encodes 16 nonstructural, 4 structural, and 9 accessory proteins. 13 It infiltrates cells by binding to human cell surface receptors such as angiotensin-converting enzyme 2 (ACE2) and possibly other cell receptors such as CD147 14 via its spike glycoprotein, which upon cleavage by human proteases enables virus−cell membrane fusion ( Figure 1A) . 3, 15, 16 Once inside, the viral RNA genome is released into the cytoplasm. Its 5′ end is translated by the host protein synthesis machinery to polyproteins (pp1a and pp1ab) that are cleaved by virusencoded proteases (M pro and PL pro ) to 16 constituent nsps. 17 The viral RTC is formed from nsp2−16 18 and plays two crucial functions: (i) transcription of subsets of the viral genome to produce mRNAs that are translated into accessory and structural proteins and (ii) replication of the full-length +ssRNA genome. The viral proteins are then assembled into a virion consisting of the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins, with the latter encapsidating the +ssRNA. 18 Multiple virions leave from a single infected cell.

SARS-CoV-2 replication involves RNA synthesis, proofreading, and modification/capping. Viral RNA synthesis is catalyzed by the C-terminal RdRp domain of nsp12 with the help of nsp7 and nsp8 cofactors. 8, 19, 20 RNA proofreading, the maintenance of the SARS-CoV-2 genome integrity, is carried out by the N-terminal 3′−5′ exoribonuclease (ExoN) domain of nsp14, which recognizes erroneous nucleotides and catalyzes their excision. 21 The nsp14 ExoN is stabilized by the nsp10 zinc-finger protein, which enhances its nucleolytic activity. 22 Viral RNA capping, the addition of a cap structure to the newly synthesized viral mRNAs, ensures their efficient translation by host cell ribosomes and evasion of the host immune response. Without the cap structure, the viral RNA molecules are degraded and may be detected as "non-self" by the host, triggering innate immune responses. 17 SARS-CoV-2 mRNA cap synthesis involves nsp10 and four enzymes, viz., (i) nsp13 helicasetriphosphatase, (ii) an unknown guanylyltransferase (GTase), (iii) nsp14 C-terminal (N7 guanine)-methyltransferase (N7-MTase), and (iv) nsp16 2′-O-methyltransferase (2′-O-MTase). nsp10 serves as an allosteric activator of the two methyltransferase enzymes and stabilizes the conserved domains involved in fidelity control (nsp14) and mRNA capping (nsp13−16). 17, 21 Figure 1B summarizes the reactions involved in capping newly synthesized viral mRNA (pppN-RNA).

The viral proteins responsible for RNA synthesis, proofreading, and capping (nsp7, -8, -10, -12−14, and -16) form the RTC core. The following mechanism to produce stable viral RNA has been proposed: 20, 21 First, a RNA template is unwound by nsp13 helicase and subsequently translocated to the nsp12 active site where a nascent ssRNA is synthesized. 20 The neighboring nsp14 excises any erroneous nucleotides from the nascent pppN-RNA, which is dephosphorylated by nsp13. An unknown GTase, nsp14, and nsp16 cap the viral ppN-RNA yielding m7 GpppNm-RNA. nsp10, an allosteric activator of nsp14 and nsp 16, acts as a molecular connector between proofreading and capping activities. 21 Because the RTC core is indispensable for SARS-CoV-2 replication, using clinically safe drugs to target its constituent proteins would reduce viral load.

Interestingly, the nsp3 PL pro domain, nsp10 zinc-finger, nsp12, nsp13, and nsp14 possess several Zn 2+ sites that are conserved among β-coronaviruses. 23 The Zn 2+ sites in these nsps serve an essential structural role 19,23−26 as well as a vital catalytic role for nsp13 helicase activity 26 and nsp14 ExoN exoribonuclease activity. 24 Among the multiple Zn 2+ sites in SARS-CoV-2, the structural Zn 2+ sites in nsp3 PL pro and nsp10 have been found to be labile, 23 i.e., Zn 2+ ions that contribute to structural stability are released upon reaction of the Zn 2+bound Cys thiolates with Zn 2+ -ejecting agents. 27−30 However, it is not known whether the Zn 2+ sites in nsp13 and nsp14, which constitute the RTC, are also labile and can be targeted by clinically safe Zn 2+ -ejector drugs such as disulfiram, an approved antialcoholic drug, and ebselen, in phase III clinical trials for hearing loss. To address this possibility, we have overexpressed SARS-CoV-2 nsp13 and nsp14 proteins to see if their Zn 2+ ions could be ejected by Zn 2+ -ejecting agents and if clinically safe disulfiram and ebselen can inhibit their enzymatic activities. On the basis of the finding herein that the Zn 2+ -ejector drugs could indeed inhibit the enzymatic activities of SARS-CoV-2 nsp13 and nsp14, we further assessed if disulfiram/ebselen combined with remdesivir, which stops RNA synthesis, could synergistically inhibit SARS-CoV-2 replication.

■ RESULTS Zn 2+ Ions Are Released from SARS-CoV-2 nsp13 and nsp14 by Zn 2+ -Ejecting Agents. His-tagged full-length SARS-CoV-2 nsp13 and nsp14 were expressed in Escherichia coli, and the recombinant proteins were purified by chromatographic methods to a high homogeneity (Figure 2a ,b). After incubating SARS-CoV-2 nsp13 and nsp14 with the Zn 2+specific fluorophore FluoZin-3 (1 μM), a Zn 2+ -ejecting compound (5 μM) was added. Ten Zn 2+ -ejecting compounds were tested: 2,2′-dithiobisbenzothiazole (also known as thiofide), cystamine dihydrochloride, 5,5′-dithiobis2-nitrobenzoic acid (DTNB), phenyl disulfide, 3-nitrobenzamide, tetraethylthiuram disulfide (disulfiram), 2,2′-dithiodipyridine (aldrithiol-2), (±)alpha-lipoic acid, ebselen, and cisplatin. Release of Zn 2+ ions was monitored by the increase of the fluorescence signal from FluoZin-3 ( Figure 2c ). Five of the Zn 2+ -ejecting compounds (DTNB, aldrithiol-2, disulfiram, thiofide, and ebselen) effectively ejected Zn 2+ ions from the SARS-CoV-2 nsp13 and nsp14 proteins.

Disulfiram and Ebselen Inhibit SARS-CoV-2 nsp13 ATPase Activity. SARS-CoV-2 nsp13 consists of an Nterminal Zn 2+ -binding domain that is connected to an inserted domain (1B) by a stalk region and two RecA ATPase domains. These domains work together to complete the helicase unwinding function. 26, 31 The Zn 2+ -binding domain is not directly involved in unwinding double-stranded DNA/RNA, but nevertheless, it is critical for nsp13 helicase activity. 32 Can the release of Zn 2+ ions from SARS-CoV-2 nsp13 affect its helicase activity? To address this, we exploited the following: SARS-CoV-2 nsp13 is an NTP-dependent helicase, and its unwinding activity/helicase activity depends on ATPase activity. 26 Hence, we measured the ATPase activity of SARS- CoV-2 nsp13 by the molybdenum blue method 33 in the presence and absence of disulfiram/ebselen to examine if these Zn 2+ -ejecting compounds can inhibit nsp13 enzymatic activity. The relative ATPase activities of nsp13 were estimated from the concentration of phosphate ions produced during ATP hydrolysis in the presence of single-stranded DNA and disulfiram (0.2−12.5 μM) or ebselen (0.2−10.0 μM) ( Figure  3 ). The Zn 2+ -ejecting assays in Figure 2c suggest that Zn 2+ ions can be ejected comparably by disulfiram and ebselen after 10 min incubation with nsp13. We thus incubated nsp13 with disulfiram/ebselen for 10 min and then measured nsp13 ATPase activity. On the basis of the measurements, disulfiram and ebselen inhibited the ATPase activity of nsp13 with comparable log IC 50 values of 2.6 and 2.5 nM, respectively. The corresponding IC 50 values indicate that ebselen (IC 50 = 291 nM) is slightly more potent than disulfiram (IC 50 = 410.7 nM), consistent with its slightly more efficient Zn 2+ release from nsp 13 in the reaction time of 10 min (600 s, Figure 2c ).

Disulfiram and Ebselen Inhibit SARS-CoV-2 nsp14 Exoribonuclease Activity. SARS-CoV nsp14 has two zincfinger motifs (Zf1 and Zf2) in the ExoN domain responsible for proofreading and one zinc-finger motif (Zf3) in the N7-MTase domain involved in mRNA capping. 24 Truncating the C-terminal region of Zf3 disrupted local hydrophobic interactions, causing a decrease in the N7-MTase activity. 24 To see if release of Zn 2+ cations from SARS-CoV-2 nsp14 Disulfiram/Ebselen and Remdesivir Exhibit Synergistic Antiviral Activity. Remdesivir, an adenosine analog RdRp inhibitor, has gained emergency FDA approval to treat acute COVID-19 patients. 9,34 It outcompetes the natural ATP substrate for binding to nsp12 RdRp, and upon RNA chain elongation, its cyano (CN) group has steric clashes with RdRp, inducing delayed chain termination. 34−36 Although remdesivir is better than other nucleotide analogs in avoiding removal by the proofreading nsp14 ExoN, it may still be removed by nsp14, as it is more effective in a model β-coronavirus (murine hepatis virus) lacking the proofreading ExoN activity compared to that of the wild-type virus, as well as in viral mutants with reduced exonuclease activity: 37, 38 Indeed, remdesivir has shown only moderate success in clinical studies: The ACTT-1 trial 39 reported that remdesivir moderately reduced time to recovery, but the WHO SOLIDARITY trial did not. 40 Mortality results from four trials of remdesivir suggested some benefit in only low-risk patients. 40 We hypothesize that inhibition of SARS-CoV-2 proofreading activity by disulfiram/ebselen may allow remdesivir to escape nsp14 ExoN-mediated removal; thus, combining remdesivir with disulfiram/ebselen may help to improve inhibition of viral Figure 5A ). 41 To see if remdesivir combined with disulfiram/ebselen could exhibit synergistic inhibition of SARS-CoV-2 replication, Vero E6 cells were treated with a given concentration of remdesivir and/or disulfiram/ebselen ( Figures S1A and S2A) . Figure 5B ,C shows the SARS-CoV-2 infection rate as the mean and corresponding standard deviation of four replicates. Disulfiram/ebselen combined with remdesivir exhibited enhanced antiviral effect compared to each drug alone with p values < 0.05. To quantify the synergistic antiviral effect, the synergy score between two drugs was calculated using the SynergyFinder. 42 As there are different reference models for quantifying degrees of synergy and their synergy scores may sometimes disagree, we used several well-known models that are based on different assumptions (dose−response-independent scores, HSA and Bliss, and dose−response-dependent scores, ZIP). 43 All models gave consistent results; hence, we report the ZIP score below. To make our prediction robust, we consider interaction between two drugs to be synergetic if the average ZIP score is >10, i.e., >10% of response beyond expectation, antagonistic if it is < −10, and additive if it is between −10 and 10. The ZIP scores between disulfiram and remdesivir are ≥0 for all concentrations with a mean of 11.4 for the most synergistic area and a maximum of 23.7, indicating synergistic interaction ( Figure S1B ). The ZIP scores between ebselen and remdesivir are also ≥0 for all concentrations; its average value for the most synergistic area is 24.6 with a maximum of 32.7, indicating synergistic interaction ( Figure S2B ). The results verify that remdesivir combined with disulfiram/ebselen show synergistic SARS-CoV-2 inhibition, and the synergy is greater when doses of the drug pair are increased.

The RTC core, which plays critical roles in SARS-CoV-2 replication as well as evasion of nucleoside analog drugs and innate immune responses, is evidently an important drug target. To date, drugs have been developed/repurposed to target a specific component of this complex such as nsp12 RdRp. 3, 44 In sharp contrast, we employ clinically safe Zn 2+ejector drugs to target multiple conserved sites in the RTC core. We show that disulfiram/ebselen can target conserved Zn 2+ sites in nsp13 and nsp14, and their combination with remdesivir can synergistically inhibit SARS-CoV-2 replication in Vero E6 cells. We propose the following mechanism for the observed effects: By ejecting Zn 2+ from the nsp13 Zn 2+ -binding domain, which is crucial for helicase and triphosphatase activities and interactions with nsp12, 26,31 disulfiram/ebselen not only inhibits nsp13 enzymatic activities but also may disrupt nsp12nsp13 interactions and affect nsp12 RdRpcatalyzed synthesis of viral RNA. It may also affect virus−host interactions since many human proteins involved in organization of the centrosome and Golgi, transcriptional regulation, protein kinase A and immune signaling, and vesicle trafficking have been identified as interacting with nsp13 using affinity purification of 26 SARS-CoV-2 proteins followed by mass spectrometry. 45 Notably, nsp13 targets innate immune signaling proteins along the interferon and nuclear factor-κB (NF-κB) pathways. 45, 46 By ejecting "structural" Zn 2+ ions from the nsp14 ExoN domain, disulfiram/ebselen can inhibit SARS-CoV-2 nsp14 exoribonuclease activity. This would mitigate the efficacy of nsp14 to excise erroneous nucleotides and allow nucleotide/nucleoside analog drugs such as remdesivir to inhibit viral RNA synthesis. In addition to nsp13 and nsp14, disulfiram/ebselen can also eject "structural" Zn 2+ from the conserved nsp10 zinc finger domain, 23 which would destabilize the nsp10−nsp14−nsp16 complex that is essential for mRNA capping (see Figure 1 ). 17, 47, 48 This would allow the host's antiviral sensors to detect viral uncapped RNA, which can be degraded, and to prevent the virus from evading host immune responses.

Altogether, this work and previous studies show that disulfiram/ebselen can target multiple conserved sites in the viral RTC that are crucial for SARS-CoV-2 RNA genome replication as well as translation of the viral proteins ( Figure  1 ). It can destabilize nsp10 cofactor, 23 a crucial mediator of protein−protein interactions, and inhibit the enzyme activities of nsp3 PL pro , 23 nsp5 M pro , 6 nsp13, and nsp14, and probably nsp12 and nsp16 through their interactions with nsp13 and nsp10−nsp14, respectively. Disulfiram/ebselen can target not only the Zn 2+ -bound cysteines but also catalytic cysteines 23 and thereby inhibit SARS-CoV-2 M pro , 6 which does not possess a Zn 2+ -site. By inhibiting M pro and PL pro viral proteolysis, disulfiram/ebselen can prevent efficient cleavage of the replicase polyproteins into component nsps. In case the virus produces resistance against these proteases, disulfiram/ ebselen can also inhibit the RTC core that is crucial for viral RNA synthesis, proofreading, and capping, thus restoring remdesivir's ability to function as a delayed chain terminator. As SARS-CoV-2 nsp3, nsp5, nsp13, and nsp14 enzymes target the interferon and/or NF-κB pathway, 45, 46 their inhibition by disulfiram/ebselen may help to restore innate immune responses.

Unlike most studies that target a specific viral protein such as M pro5,6 or the spike protein 1,2 by developing potent (nanomolar) inhibitors or antibodies, our strategy simultaneously targets multiple conserved viral proteins responsible for viral polypeptide proteolysis as well as viral genome replication and viral protein translation using clinically safe Zn 2+ -ejector drugs. This has several advantages: Whereas a single viral drug target such as M pro or the spike protein can undergo mutations to produce resistance against specific drugs, it would be less likely for the multiple conserved viral proteins that are jointly responsible for viral replication and transcription to simultaneously mutate and achieve drug resistance. Mutations of the conserved Zn 2+ -binding cysteines in nsp3, nsp10, and nsp12− 14 that are targeted by disulfiram/ebselen would likely disrupt binding to Zn 2+ cations that serve essential structural and/or catalytic roles in several SARS-CoV-2 proteins. Furthermore, disulfiram/ebselen targets the "upstream" part of the SARS-CoV-2 life cycle ( Figure 1 ) before multiple replicated viruses leave the infected cell. Importantly, disulfiram is inexpensive, widely available, and easily administered, and may allow other broad-spectrum antivirals to synergistically inhibit a new virus, as shown herein. A third advantage is that our strategy is not specific to a particular SARS-CoV-2 variant or any type of coronavirus. This is because the proteins essential for RNA replication such as the RTC core are the most conserved among coronaviruses. Indeed, analysis of the SARS-CoV-2 gene sequences show the least divergence in the gene encoding these conserved domains (https://nextstrain.org/ncov/ global). Thus, our approach may prove useful not only for the current COVID-19 pandemic but also in future coronavirus outbreaks where it may be deployed as a first line of defense in the absence of monoclonal antibodies and vaccines. In summary, we show that clinically safe Zn 2+ -ejector drugs (disulfiram/ebselen) can target conserved functionally important Zn 2+ sites in the multiprotein RTC and, when combined with remdesivir, that these can synergistically inhibit SARS-CoV-2 replication in Vero E6 cells ( Figure 6 ).

Protein Expression and Purification. The cDNA of SARS-CoV-2 nsp13 (residues 5302−5902 of pp1a/pp1ab) and nsp14 (residues 5903−6429 pp1a/pp1ab) were synthesized from Protech, Inc. (Taiwan) and cloned into pET28a and pRSFDuet-1 vectors, respectively, for expression of the Nterminal His-tagged nsp13 and the C-terminal His-tagged nsp14. Both plasmids were transformed into E. coli BL21 (DE3) pLysS strain cultured in LB medium supplemented with 50 μg/mL kanamycin. Cells were grown to an optical density of 0.6 measured at a wavelength of 600 nm and induced by 0.2 mM IPTG at 18°C for 14−16 h to express His-tagged SARS-CoV-2 nsp13 and nsp14.

The harvested cells expressing nsp13 were disrupted by a microfluidizer (Microfluidics M-110P) in lysis buffer containing 50 mM Tris-HCl (pH 8.0), 500 mM NaCl, protease inhibitor, 5% glycerol, and 10 mM β-mercaptoethanol. The supernatant was run through a HisTrap FF column (5 mL, GE HealthCare) and washed with a washing buffer containing 50 mM Tris-HCl (pH 8.0), 200 mM NaCl, 5% glycerol, and 30 mM imidazole. The eluted nsp13 was further purified by a HiTrap SP HP column (5 mL, GE HealthCare) to produce a homogeneous nsp13 protein sample.

For the purification of nsp14, the harvested cells were resuspended in lysis buffer (20 mM HEPES (pH 7), 150 mM NaCl, 4 mM MgCl 2 , 5% glycerol, and 10 mM βmercaptoethanol). After homogenization, the supernatant was loaded into a HisTrap FF column (5 mL, GE HealthCare) and washed with a washing buffer containing 20 mM HEPES (pH 7.0), 150 mM NaCl, 4 mM MgCl 2 , 5% glycerol, 10 mM βmercaptoethanol, and 40 mM imidazole. The protein sample was collected and further loaded into a gel filtration column (HiLoad 16/60 Superdex 200, GE HealthCare), then eluted by a buffer of 50 mM HEPES (pH 7.4), 50 mM NaCl, 5 mM MgCl 2 , and 5% glycerol.

Zn 2+ -Ejection Assays. Zn 2+ -ejecting agents were purchased from Sigma-Aldrich (USA), including 2,2′-dithiobis-(benzothiazole), cystamine dihydrochloride, 5,5′-dithiobis(2nitrobenzoic acid) (DTNB), phenyl disulfide, 3-nitrobenzamide, tetraethylthiuram disulfide (disulfiram), 2,2′-dithiodipyridine, (±)alpha-lipoic acid, ebselen, and cisplatin. The Zn 2+specific fluorophore FluoZinTM-3 (Invitrogen/Life Technologies) was used to monitor the release of Zn 2+ ions from SARS-CoV-2 nsp13 and nsp14. The Zn 2+ -ejecting agents were dissolved in DMSO to a stock solution of 100 μM. SARS-CoV-2 His-tagged nsp13 (5 μM) and nsp14 (5 μM) were respectively mixed with each Zn 2+ -ejecting agent (5 μM) and FluoZin-3 (1 μM) in a total reaction volume of 200 μL at room temperature. Fluorescence emission was then measured by EnSpire Multilabel Plate Reader (PerkinElmer, USA) at an excitation wavelength of 494 nm and emission wavelength of 516 nm.

Inhibition of the nsp13 ATPase Activity by Zn 2+ Ejector Drugs. ATPase activity of SARS-CoV-2 nsp13 was analyzed by the molybdenum blue method 33 to measure the phosphate ion concentration in ATP hydrolysis reaction in the presence of the Zn 2+ ejector drugs disulfram and ebselen. nsp13 (2.5 μM, 10 μL) was mixed with or without disulfiram (2−125 μM, 10 μL) or ebselen (0.2−100 μM, 10 μL) in 60 μL of the reaction buffer containing 33 mM Tris-HCl (pH 8.0) and 5 mM MgCl 2 at room temperature for 10 min. ATP (50 mM, 10 μL) and ssDNA (2.5 μM, 10 μL) with a sequence of 5′-(dT) 24 -3′ were then added into the nsp13 solution and incubated for 10 min. The ATPase reaction was stopped by adding 100 μL of 10% SDS, and the blue complexes between inorganic phosphate and molybdate were developed by adding 100 μL of 1.25% ammonium molydbate in 6.5% sulfuric solution and 100 μL of freshly prepared 10% (w/v) ascorbic acid. A total of 400 μL of reaction solution was incubated at 25°C for 10 min and then read at 660 nm by Enspire plate reader (PerkinElmer). Various concentrations of Na 2 HPO 4 ranging from 0.05 to 0.5 mM were also prepared as a standard curve. The relative ATPase activity of SARS-CoV-2 nsp13 in the Figure 6 . Disulfiram and ebselen can target multiple SARS-CoV-2 nsps to block the viral polyprotein cleavage and RNA replication/transcription. These Zn 2+ -ejector drugs target PL pro of nsp3 and M pro of nsp5 to inhibit viral polypeptide proteolysis. They also directly target nsp10, nsp13, and nsp14 as well as indirectly target nsp12 and nsp16 to inhibit viral RNA genome replication and translation of the structural and accessory viral proteins. They can act in concert with remdesivir to synergistically inhibit SARS-CoV-2 replication.

ACS Pharmacology & Translational Science pubs.acs.org/ptsci Article presence of each Zn 2+ ejector was compared to that without adding Zn 2+ ejector, and the half-maximal inhibitory activity (IC 50 ) of each inhibitor was calculated by GraphPad Prism. Inhibition of the nsp14 Exoribonuclease Activity by Zn 2+ Ejector Drugs. nsp14 (50 μM, 100 μL) was mixed with 4 μL of 5′-end FAM-labeled ssRNA (1 μM, 5′-FAM-C 7 U 30 -3′) in 200 μL of the reaction buffer (100 mM HEPES (pH 7.4), 100 mM NaCl, 10 mM MgCl 2 and 10% glycerol), and 100 μL of ddH 2 O. Disulfiram (1 μL, 0−200 μM) or ebselen (1 μL, 0− 100 μM) in different concentrations was then added to the nsp14 and RNA mixture (19 μL), and incubated for 30 min at 37°C. The RNA loading dye (20 μL, 89 mM Tris-HCl, pH 8, 89 mM boric acid, 2 mM EDTA, 0.01% bromophenol blue, 0.02% xylene cyanol FF, and 7 M urea) was then added into the mixture, and the sample was heated at 95°C for 5 min to stop the reaction. The RNA in the mixtures were separated on TBE gel and visualized by Biomolecular Imager (Amersham Typhoon, GE HealthCare). The resolved RNA bands in the gel were analyzed by ImageJ, and the IC 50 of each inhibitor was calculated by GraphPad Prism.

Cell-Based Assays. Remdesivir was produced following the previous protocol. 49 Vero E6 cells were pretreated with the disulfiram/ebselen and/or remdesivir at various concentrations for 1 h at 37°C and then adsorbed with SARS-CoV-2 TCDC#4 (hCoV-19/Taiwan/4/2020) at MOI 0.005 (100 PFU/well) for 1 h at 37°C. After virus adsorption, the cells were replenished with fresh medium and compounds at the indicated concentrations for 1 day of incubation. The cells were fixed with 10% formaldehyde, permeabilized with 0.5% Triton X-100, and stained with anti-SARS-CoV-2 N protein antibody (provided by Dr. An-Suei Yang, Genomic Research Center, Academia Sinica, Taiwan) and anti-human IgG-488. The N protein expression was measured using a high-content image analysis system (Molecular Devices), and the average infection rate of no-drug treatment was set as 100%. The synergy score is calculated using the SynergyFinder to quantify the synergistic antiviral effect between disulfiram/ebselen and remdesivir.

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsptsci.1c00022.

Synergistic antiviral potential of disulfiram with remdesivir, and synergistic antiviral potential of ebselen with remdesivir (PDF)

Taiwan Chun-Ping Chang − Institute of Biotechnology and Pharmaceutical Research

Academia Sinica, Taipei, Taiwan. We thank Taiwan CDC for providing SARS-CoV-2 TCDC#4 (hCoV-19/Taiwan/4/2020) and funding support from Academia Sinica for IBMS P3 facility (AS-CFII-108-102) and the Ministry of Science and Technology, Taiwan for COVID-19 study (MOST 109-3114-Y-001-001). We thank Dr. Karine Mazmanian for help with the figures. We acknowledge the DNA Sequencing Core Facility (IBMS, AS-CFII-108-115) of the Scientific Instrument Center in Academia Sinica for DNA sequencing

Therapy for early COVID-19: A critical need

SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid

Potential therapeutic agents and associated bioassay data for COVID-19 and related human coronavirus infections

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved αketoamide inhibitors

Structure of M pro from COVID-19 virus and discovery of its inhibitors

Can papain-like protease inhibitors halt SARS-CoV-2 replication?

Structure of the RNA-dependent RNA polymerase from COVID-19 virus

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses (2020) The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

The nonstructural proteins directing coronavirus RNA synthesis and processing

Coronavirus biology and replication: implications for SARS-CoV-2

Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors

Architecture of a SARS-CoV-2 mini replication and transcription complex

A structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading and final capping

Coronavirus Nsp10, a critical co-factor for activation of multiple replicative enzymes

Multi-targeting of functional cysteines in multiple conserved SARS-CoV-2 domains by clinically safe Zn-ejectors

Structural basis and functional analysis of the SARS coronavirus nsp14−nsp10 complex

Crystal structure of Middle East respiratory syndrome coronavirus helicase

Delicate structural coordination of the Severe Acute Respiratory Syndrome coronavirus Nsp13 upon ATP hydrolysis

Anti-HIV agents that selectively target retroviral nucleocapsid protein zinc fingers without affecting cellular zinc finger proteins

Structure of a zinc-binding domain in the Junin virus envelope glycoprotein

Factors controlling the role of Zn and reactivity of Zn-bound cysteines in proteins: Application to drug target discovery

Using an old drug to target a new drug site: Application of disulfiram to target the Zn-site in HCV NS5A protein

Structural basis for helicase-polymerase coupling in the SARS-CoV-2 replication-transcription complex

A complex zinc finger controls the enzymatic activities of nidovirus helicases

A modified molybdenum blue method for orthophosphate determination suitable for investigating enzymatic hydrolysis of organic phosphates

Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of COVID-19

Remdesivir for COVID-19: A review of pharmacology, mechanism of action, in-vitro activity and clinical use based on available case studies

Remdesivir is a directacting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency

Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease

Remdesivir is a Delayed Translocation Inhibitor of SARS CoV-2 Replication

Remdesivir for the treatment of Covid-19 final report

Repurposed antiviral drugs for COVID-19interim WHO SOLIDARITY trial results

Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active sites

SynergyFinder 2.0: visual analytics of multi-drug combination synergies

Applying synergy metrics to combination screening data: agreements, disagreements and pitfalls

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Crystal structure and functional analysis of the SARS-coronavirus RNA cap 2'-Omethyltransferase nsp10/nsp16 complex